MEI reports Phase Ib data for ME-401 in hematologic malignancies

MEI Pharma Inc. (NASDAQ:MEIP) reported data from 29 evaluable patients with relapsed or refractory follicular lymphoma or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in a Phase Ib trial showing that once-daily ME-401 led to an overall response rate (ORR) of 83%. ME-401 was well tolerated with dose-limiting toxicities (DLTs) reported. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, dose-escalation, U.S. and Swiss trial is also evaluating ME-401 in combination with Rituxan rituximab. ME-401 is a phosphoinositide 3-kinase (PI3K) delta inhibitor...